Members of the GLIOTRAIN Consortium publish GBM state of the art position paper

Several members of the GLIOTRAIN consortium along with key collaborators Prof Roel Verhaak (The Jackson Laboratory , Farmington, CT, USA), Mr David O’Brien and Mr James Clerkin (National Neurosurgical Department, Beaumont Hospital, Dublin, Ireland) have recently published (September 2020) a state of the art position paper discussing novel treatment approaches and ongoing trials in the IDH-wildtype glioblastoma (GBM) setting. In this paper, we propose an integrated drug discovery stratagem incorporating multi-omics, single cell technologies and computational approaches to advance the field and provide novel therapeutic targets and treatments, with an overall goal to improve GBM patient outcomes. You can access the paper freely at this link